Abstract：Objective To explore the relationship between auroral kinase B (AURKB) and anti-apoptosis protein repeat 5 (BIRC5) expression levels and clinicopathological features and prognosis in prostate cancer (PCa).Methods A total of 152 PCa patients admitted to our hospital from October 2018 to October 2020 were selected as the study objects. Cancer tissue specimens were included in PCa group (152 cases), and corresponding paracancer tissue specimens were included in paracancer group (152 cases). AURKB and BIRC5 expression were detected by immunohistochemical -method. The relationship between AURKB and BIRC5 expression and clinicopathological features of PCa patients was analyzed. The related factors affecting the prognosis of PCa patients were explored by multivariate Cox regression.Results The positive expression rates of AURKB and BIRC5 in PCa group were higher than those in paracancer group (all P<0.05). The AURKB positive expression rate and BIRC5 positive expression rate in PCa cases with Gleason score ≥7, lymph node metastasis and TNM stage Ⅲ to Ⅳ were higher than those with Gleason score < 7, no lymph node metastasis and TNM stage Ⅰ to Ⅱ (all P<0.05). The patients were followed up for a duration of 3 years, during which 73 individuals survived, resulting in an overall survival rate of 68.42% (104/152). The 3-year overall survival rate among PCa patients exhibited significant correlations with Gleason score, lymph node metastasis, and TNM stage and so on (all P<0.05). The 3-year overall survival rate of AURKB and BIRC5 negative patients was higher than that of AURKB and BIRC5 positive cases (all P<0.05). Multivariate Cox regression analysis showed that Gleason score≥7, lymph node metastasis, TNM stage Ⅲ to Ⅳ, AURKB positive and BIRC5 positive were the prognostic factors of PCa patients (all P<0.05).Conclusions The expression levels of AURKB and BIRC5 are significantly upregulated in cancer tissues of PCa patients, exhibiting a close correlation with clinicopathological features and prognosis. These findings suggest that AURKB and BIRC5 hold great potential as prognostic markers for assessing the survival outcomes of PCa patients.
